Cao Sean Wuxiong exercised Options for 339,372 NovaBridge Biosciences shares across two transactions on 2026-09-03. The transactions leave the chief Business development officer with 374,445 shares, while his derivative-securities holding stood at 135,960, giving investors an updated view of his reported ownership.
Key Highlights
- The transactions were recorded on 3 September 2026 under SEC transaction code M.
- The exercises involved 147,553 derivative securities at $0 per share.
- Cao Sean Wuxiong held 135,960 derivative securities after the transactions.
NovaBridge Biosciences (NASDAQ: NBP) officer Cao Sean Wuxiong exercised options for 339,372 shares across two transactions. The chief business development officer held 374,445 shares after the transactions.
Option Exercise Covers 147,553 Derivative Securities
The transactions also involved 147,553 derivative securities. Those securities were exercised at $0 per share. The activity was recorded on 3 September 2026. Cao Sean Wuxiong held 135,960 derivative securities following the transactions.
FAQs
Q: What did Cao Sean Wuxiong exercise at NovaBridge Biosciences?
A: Cao Sean Wuxiong exercised options for 339,372 NovaBridge Biosciences shares across two transactions. The filing identifies the transactions as occurring on 3 September 2026.
Q: What was the exercise price for the derivative securities?
A: The 147,553 derivative securities involved in the transactions were exercised at an exercise price of $0 per share. The activity was recorded on 3 September 2026.
Q: How many NovaBridge Biosciences securities did Cao Sean Wuxiong own afterward?
A: Following the transactions, Cao Sean Wuxiong owned 374,445 NovaBridge Biosciences shares. The filing also reported that he owned 135,960 derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.